Attention!

What is the drug EUMYLEO®:

Dimethyl fumarate has an anti-inflammatory and immunomodulatory effect.

Dimethyl fumarate and its main metabolite, monomethylfumarate, have also been shown to significantly reduce immune cell activity and the subsequent release of pro-inflammatory cytokines in response to an induced inflammatory response. In patients with psoriasis, dimethyl fumarate affects the phenotype of lymphocytes by reducing the formation of pro-inflammatory cytokines (ТН1, Tn17), and increasing the production of anti-inflammatory cytokines (TН2). The therapeutic activity of dimethyl fumarate was confirmed in the modeling of inflammation and neuroinflammatory trauma. During the first year, the use of dimethyl fumarate may be accompanied by a decrease in the total number of lymphocytes in the blood, on average by 30% from the initial value, followed by its stabilization.

Dosage form

Dosage 120 mg: Solid gelatin opaque capsules No. 0el with a white body and a bluish-green lid. The contents of the capsules are 2 round, biconvex tablets, enteric-soluble, white-coated. On a cross-section, the tablet core is white or almost white in color.

Dosage 240 mg: Solid gelatin opaque capsules No. 0el with a bluish-green body and lid. The contents of the capsules are 4 round, biconvex tablets, enteric-soluble, white-coated. On a cross-section, the tablet core is white or almost white in color.

Indications for use

EUMYLEO® is indicated for the treatment of adult patients with relapsing - remitting multiple sclerosis.

Efficacy and safety studies

In accordance with current legislation, the drug has proven its effectiveness, safety and quality during state registration. For registration purposes, a bioequivalence study was conducted with the original (reference) medicinal product.